Dr. Yvonne Greenstreet Joins Pfizer As Senior Vice President And Head Of Medicines Development, Specialty Care Business Un

COLLEGEVILLE, Pa.--(BUSINESS WIRE)-- Pfizer Inc. today announced that Dr. Yvonne Greenstreet has been appointed Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit, effective February 1 2011.

Dr. Yvonne Greenstreet (Photo: Business Wire)

Dr. Yvonne Greenstreet (Photo: Business Wire)

Upon her arrival, she will assume global responsibility for leading the advancement of the development portfolio, ensuring its alignment with Specialty Care’s strategic objectives.

“Yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry,” said Geno Germano, president and general manager of Pfizer’s Specialty Care Business Unit. “Her experience in delivering medicines in challenging markets is noteworthy, and she will play an important role in advancing Specialty Care’s commitment to the eradication, remission and relief of serious diseases.”

Dr. Greenstreet takes over for Dr. Michael Berelowitz, who is retiring after a distinguished 14-year career at Pfizer. She will report directly to Germano, and join his leadership team.

Dr. Greenstreet joins Pfizer after an 18-year career with GlaxoSmithKline (GSK), where she most recently was Senior Vice president and Chief of Strategy, Research and Development. Her work spans the R&D continuum, including clinical development, medical affairs, health economics, outcomes research, regulatory affairs and portfolio management. At GSK, she was responsible for leading the development of small molecules and biologics in several therapeutic areas, including musculoskeletal, immunology/inflammation, gastrointestinal, urology, ophthalmology and anti-infectives. She had also been responsible for clinical development and medical affairs for GSK’s European business.

Before joining GSK, Dr. Greenstreet practiced medicine in the United Kingdom National Health Service and gained experience in medicine at a number of leading teaching hospitals in London. She holds a degree in medicine from the University of Leeds, UK, and an MBA from INSEAD, Fountainbleau, France.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6591235&lang=en



CONTACT:

Pfizer Inc.
Victoria Davis, 212-733-3227

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo
Photo
 Photo
Dr. Yvonne Greenstreet (Photo: Business Wire)

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.